How have CRPOF shares performed in 2024?

Ceapro's stock was trading at $0.1652 at the beginning of the year. Since then, CRPOF shares have increased by 7.2% and is now trading at $0.1771. View the best growth stocks for 2024 here .

When is Ceapro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our CRPOF earnings forecast .

How do I buy shares of Ceapro?

Shares of CRPOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CRPOF

Ceapro (CRPOF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CRPOF Stock Alerts

$0.18

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.18
▼
$0.18
50-Day Range: $0.12
▼
$0.18
52-Week Range: $0.11
▼
$0.44

Volume: N/A
Average Volume: 10,393 shs
Market Capitalization: $13.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Headlines Short Interest

Get Ceapro alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Ceapro Stock (OTCMKTS:CRPOF)

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

CRPOF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRPOF Stock News Headlines

March 28, 2024 | finanznachrichten.de

Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

March 28, 2024 | globenewswire.com

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 12, 2024 | globenewswire.com

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

February 26, 2024 | globenewswire.com

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

February 23, 2024 | globenewswire.com

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

February 15, 2024 | globenewswire.com

Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris

December 13, 2023 | finance.yahoo.com

Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 29, 2023 | msn.com

Ceapro GAAP EPS of -C$0.01, revenue of C$2.62M

November 7, 2023 | finance.yahoo.com

Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology

July 18, 2023 | finance.yahoo.com

Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

June 7, 2023 | finanznachrichten.de

Ceapro Inc.: Ceapro Announces Results of 2023 Shareholders' Meeting

June 7, 2023 | finance.yahoo.com

Ceapro Announces Results of 2023 Shareholders’ Meeting

April 27, 2023 | finance.yahoo.com

Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations

April 26, 2023 | theglobeandmail.com

Closing Bell: Ceapro Inc flat on Tuesday (CZO)

April 25, 2023 | theglobeandmail.com

Closing Bell: Ceapro Inc flat on Monday (CZO)

April 13, 2023 | theglobeandmail.com

Closing Bell: Ceapro Inc down on Thursday (CZO)

March 23, 2023 | finance.yahoo.com

Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

March 14, 2023 | finance.yahoo.com

Ceapro Inc. (CRPOF) Stock Historical Prices & Data - Yahoo Finance

March 8, 2023 | finance.yahoo.com

Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

February 21, 2023 | finance.yahoo.com

Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company

January 10, 2023 | finance.yahoo.com

Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event

December 22, 2022 | msn.com

Ceapro receives approval to begin human trial for anti-inflammatory drug

December 22, 2022 | technews.tmcnet.com

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

November 9, 2022 | finance.yahoo.com

Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

November 7, 2022 | finance.yahoo.com

Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

See More Headlines

Receive CRPOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ceapro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/23/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:CRPOF
CUSIP: N/A
CIK: N/A
Web: www.ceapro.com
Phone: (780) 421-4555
Fax: 780-421-1320
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $3.38 million
Net Margins: -24.95%
Pretax Margin: -31.44%
Return on Equity: -8.91%
Return on Assets: -7.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.00
Quick Ratio: 7.72

Sales & Book Value

Annual Sales: $14.49 million
Price / Sales: 0.96
Cash Flow: $0.06 per share
Price / Cash Flow: 2.86
Book Value: $0.32 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 78,290,000
Free Float: N/A
Market Cap: $13.87 million
Optionable: Not Optionable
Beta: 1.53

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Gilles R. Gagnon ICD.D (Age 70)
M.B.A., M.Sc., CEO, President & Director
Comp: $412.31k
Ms. Stacy Prefontaine C.A.
CPA, CA, CPA, CFO & Corporate Secretary
Dr. Bernhard Seifried
Senior Director of Research & Technology
Mr. Michel Regnier P. Eng.
Senior Vice President of Technical Operations

Key Competitors

View All Competitors

CRPOF Stock Analysis - Frequently Asked Questions

How have CRPOF shares performed in 2024?: Ceapro's stock was trading at $0.1652 at the beginning of the year. Since then, CRPOF shares have increased by 7.2% and is now trading at $0.1771.
View the best growth stocks for 2024 here.
When is Ceapro's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our CRPOF earnings forecast.
How do I buy shares of Ceapro?: Shares of CRPOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CRPOF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial